Loading

Please wait...

Synagis

Generic Name: palivizumab (PAL i VIZ oo mab)
Brand Names: Synagis
Synagis is used to prevent lung disease caused by respiratory syncytial virus. Learn about side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Synagis

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Synagis (palivizumab) is a man-made antibody to respiratory syncytial virus (RSV). RSV can cause serious illness in children. Palivizumab helps keep RSV cells from multiplying in the body. Synagis is used to prevent serious lung disease caused by respiratory syncytial virus in premature infants, and infants born with certain lung disorders or heart disease. Synagis works best in children who are 24 months old or younger at the beginning of RSV season (6 months or younger for premature infants). It will not treat a child who is already sick with RSV disease. Learn more

Synagis Side Effects

Synagis Side Effects

Note: This document contains side effect information about palivizumab. Some of the dosage forms listed on this page may not apply to the brand name Synagis.

For the Consumer

Applies to palivizumab: intramuscular solution

Along with its needed effects, palivizumab (the active ingredient contained in Synagis) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking palivizumab:

More common

  • Bluish color of the fingernails, lips, skin, palms, or nail beds
  • blurred vision
  • confusion
  • cough
  • difficulty with breathing
  • difficulty with swallowing
  • dizziness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fast heartbeat
  • fever
  • hives or welts
  • irregular, fast or slow, or shallow breathing
  • itching
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • loss of strength or energy
  • muscle pain or weakness
  • redness of the skin
  • shortness of breath
  • skin rash
  • sweating
  • tightness in the chest
  • unresponsiveness
  • unusual tiredness or weakness
  • wheezing

Incidence not known

  • Black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • pinpoint red spots on the skin
  • unusual bleeding or bruising

Some side effects of palivizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

For Healthcare Professionals

Applies to palivizumab: intramuscular powder for injection, intramuscular solution

Cardiovascular

Frequency not reported: Arrhythmia (during studies of congenital heart disease patients)

Gastrointestinal

Common (1% to 10%): Nausea, vomiting, diarrhea

Hypersensitivity

Frequency not reported: Anaphylaxis, anaphylactic shock (sometimes fatal)

Postmarketing reports: Angioedema

Local

Common (1% to 10%): Injection site reactions

Other

Very common (10% or more): Pyrexia

Dermatologic

Very common (10% or more): Rash

Uncommon (0.1% to 1%): Urticaria

Frequency not reported: Pruritus

General

The most serious adverse reactions are anaphylaxis and other acute hypersensitivity reactions.

Hematologic

Uncommon (0.1% to 1%): Thrombocytopenia (mild), eosinophilia (mild)

Postmarketing reports: Severe thrombocytopenia (platelet count less than 50,000/microliter)

Nervous system

Uncommon (0.1% to 1%): Convulsions

Respiratory

Frequency not reported: Cyanosis during studies of congenital heart disease patients

Postmarketing reports: Dyspnea, asthma, bronchospasm

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Synagis (www.drugs.com/synagis.html).